Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.60 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
| ▸ | TOP2A | P11388 | 6/20 | 0.47 |
| ▸ | TOP2B | Q02880 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL115999 | 0.92 | ADRB2 (0.60) | ADRB2STAT3TOP2ATOP2BKMT2A | |
| SCHEMBL12825346 | 0.91 | ADRB2 (0.59) | ADRB2STAT3TOP2ATOP2BKMT2A | |
| SCHEMBL29492858 | 0.89 | ADRB2 (0.68) | ADRB2STAT3TOP2ATOP2BKMT2A | |
| SCHEMBL2844967 | 0.89 | ADRB2 (0.68) | ADRB2STAT3TOP2ATOP2BKMT2A | |
| SCHEMBL143605 | 0.87 | ADRB2 (0.64) | ADRB2STAT3TOP2ATOP2BKMT2A | |
| SCHEMBL115991 | 0.86 | ADRB2 (0.62) | ADRB2STAT3TOP2ATOP2BKMT2A | |
| SCHEMBL7127445 | 0.86 | ADRB2 (0.62) | ADRB2STAT3TOP2ATOP2BKMT2A | |
| SCHEMBL7575069 | 0.85 | ADRB2 (0.61) | ADRB2STAT3TOP2ATOP2BKMT2A | |
| SCHEMBL9188190 | 0.85 | ADRB2 (0.61) | ADRB2STAT3TOP2ATOP2BKMT2A | |
| SCHEMBL10627001 | 0.85 | ADRB2 (0.66) | ADRB2STAT3TOP2ATOP2BKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058989-A1 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | ACHAOGEN, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120058989-A1 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | ACHAOGEN, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120058989-A1 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | ACHAOGEN, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| WO-2011031743-A1 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | ACHAOGEN, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011031743-A1 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | ACHAOGEN, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011031740-A1 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | ACHAOGEN, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011031740-A1 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | ACHAOGEN, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| EP-2250171-A2 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | Achaogen, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009137130-A2 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | ACHAOGEN, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009137130-A2 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | ACHAOGEN, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058989-A1 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | RECQL, BLVRB, NQO2 | ADRB2 702/4885STAT3 4808/4885TOP2A 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.